• SPX
  • $5,815.03
  • 0.61 %
  • $34.98
  • DJI
  • $42,863.86
  • 0.97 %
  • $409.74
  • N225
  • $39,605.73
  • 0.57 %
  • $224.91
  • FTSE
  • $8,253.65
  • 0.19 %
  • $15.92
  • IXIC
  • $18,342.94
  • 0.33 %
  • $60.89
TScan Therapeutics, Inc. (TCRX) Stock Price, News & Analysis

TScan Therapeutics, Inc. (TCRX) Stock Price, News & Analysis

Currency in USD Disclaimer

$5.38

$0.03

(0.56%)

Day's range
$5.27
Day's range
$5.4
50-day range
$4.72
Day's range
$6.81
  • Country: US
  • ISIN: US89854M1018
52 wk range
$2.86
Day's range
$9.69
  • CEO: Dr. Gavin MacBeath Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 0.13
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (TCRX)
  • Company TScan Therapeutics, Inc.
  • Price $5.38
  • Changes Percentage (0.56%)
  • Change $0.03
  • Day Low $5.27
  • Day High $5.40
  • Year High $9.69

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/06/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $12.00
  • High Stock Price Target $12.00
  • Low Stock Price Target $12.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.75
  • Trailing P/E Ratio -11.17
  • Forward P/E Ratio -11.17
  • P/E Growth -11.17
  • Net Income $-89,218,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.